Cortactin and Spine Dysfunction in Fragile X
脆性 X 细胞的 Cortactin 和脊柱功能障碍
基本信息
- 批准号:8317096
- 负责人:
- 金额:$ 3.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-10 至 2016-07-09
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcetylationActinsActomyosinAcuteAdultAffectAnatomyAngelman SyndromeAnimalsAttenuatedAutistic DisorderCell physiologyCellsCharacteristicsCognitiveCognitive deficitsComorbidityCytoskeletonDefectDendritic SpinesDepressed moodDevelopmentDiseaseEventExhibitsF-ActinFailureFamilyFragile X SyndromeFunctional disorderGTP BindingGuanosine Triphosphate PhosphohydrolasesHDAC6 geneHippocampus (Brain)Impaired cognitionImpairmentIncidenceKnock-outKnockout MiceLaboratoriesLearningLocationLong-Term PotentiationMAP Kinase GeneMeasuresMediatingMemoryMemory impairmentMicrotubulesMitogen-Activated Protein Kinase KinasesMitogensModelingModificationMolecularMonomeric GTP-Binding ProteinsMorphologyMovementMusNeurobiologyNeuronsPathway interactionsPatientsPatternPhenotypePhosphoric Monoester HydrolasesPhosphorylationPhosphotransferasesProcessProtein Phosphatase 2A Regulatory Subunit PR53ProteinsPublic HealthRegulationRegulatory PathwayResearchSerineSignal PathwaySignal TransductionSliceStreamSynapsesSynaptic plasticitySynaptosomesSystemTestingTherapeuticVertebral columnWorkautism spectrum disorderbasecognitive functioncostgenetic regulatory proteinhistone deacetylase 6human EMS1 proteinimprovedin vivoinnovative technologiesinterestmemory encodingmemory recognitionmouse modelmutantnovelp21 activated kinasepreventsuccesstherapeutic targettraffickingtransmission process
项目摘要
DESCRIPTION (provided by applicant): Autism is a devastating condition which takes a significant toll on patients, their families, and the national economy. There are no treatments for
cognitive impairments (e.g., learning and memory deficits) that affect over 75% of autistic patients. In models of many autism-associated disorders and conditions with comorbidity for autism, such Fragile X, Rett, and Angelman Syndromes, there are significant abnormalities in dendritic spine morphology, which are associated with impairments in the stabilization of long-term potentiation (LTP), a synaptic mechanism of memory encoding. Together, these findings suggest that defects in the spine actin cytoskeleton may underlie cognitive deficits in autism-associated conditions of different origin. Spine abnormalities and LTP impairments are best characterized in the Fmr1-knockout (KO) mouse model of fragile X syndrome (FXS), a condition with high (~30%) comorbidity for autism. Specifically, these mutants exhibit defects in signaling through Rac GTPase, stabilization of activity-driven changes in spine filamentous (F) actin, and consolidation of LTP. Studies by the applicant have demonstrated that movement of cortactin, a spine protein which stabilizes actin network branch points and protects F-actin from degradation, via both actomyosin and microtubule systems, is impaired at Fmr1-KO spines following LTP-induction. This suggests that the F- actin stabilization deficits in KOs may reflect disturbances in signaling to cortactin. The proposed research will build on these findings to test the specific hypotheses that (a) abnormal cortactin serine phosphorylation and acetylation, which regulate the protein's subcellular movement, both originate from a single molecular impairment and contribute to the phenotype of impaired movement following LTP induction in KOs and that (b) learning (in vivo) activates these synaptic processes in WT but not KO mice. There are 3 specific aims. Aim 1 will test if basal levels or activation of synaptic Ras or PP2A are impaired in KOs (both of these targets influence the cortactin phosphorylation and acetylation paths). Aim 2 will test if signaling through MAPK and/or HDAC6, which contribute to cortactin serine phosphorylation and acetylation, are necessary for activity- induced cortactin translocation. hippocampus-dependent spatial learning activates synaptic signaling to cortactin in the WTs and if this signaling is attenuated or absent in Fmr1-KOs in vivo. Through interrogating synaptic mechanisms associated with impairments in F-actin stabilization and determining if these abnormalities are also present in the behaving animal, the proposed studies will contribute to our understanding of synaptic plasticity in both normal and FXS model mice and offer therapeutic targets for normalization of memory function in FXS and other autistic conditions. Finally, Aim 3 will test if hippocampus-dependent spatial learning activatessynaptic signaling to cortactin in the WTs and if this signaling is attenuated or absent in Fmr1-KOs in vivo. Through interrogating synaptic mechanisms associated with impairments in F-actin stabilization and determining if these abnormalities are also present in the behaving animal, the proposed studies will contribute to our understanding of synaptic plasticity in both normal and FXS model mice and offer therapeutic targets for normalization of memory function in FXS and other autistic conditions.
PUBLIC HEALTH RELEVANCE: There are no available therapeutics for the cognitive component (e.g. learning and memory impairments) of autism, a disease with increasing incidence and staggering national costs. Building upon novel findings that stabilization of the actin cytoskeleton is abnormal in a mouse model of a disease highly associated with autism, fragile X syndrome, the proposed research will test the hypotheses that modulation of the actin-associated protein cortactin is impaired in fragile X model mice and that these regulatory pathways are critically involved in the protein's cellular functions that are engaged during learning. This work is directly relevant to public health issues by advancing our understanding of cellular processes underlying cognitive impairment with autism, a highly prevalent condition with no known cure. Moreover, and importantly, these studies are expected to identify important therapeutic targets for improving cognitive (learning) function in fragile X syndrome and potentially other autism associated disorders.
描述(由申请人提供):自闭症是一种毁灭性的疾病,对患者、他们的家庭和国家经济造成了重大损失。没有治疗方法
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ronald Robert Seese其他文献
Ronald Robert Seese的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ronald Robert Seese', 18)}}的其他基金
Cortactin and Spine Dysfunction in Fragile X
脆性 X 细胞皮质蛋白和脊柱功能障碍
- 批准号:
8839297 - 财政年份:2012
- 资助金额:
$ 3.29万 - 项目类别:
Cortactin and Spine Dysfunction in Fragile X
脆性 X 细胞的 Cortactin 和脊柱功能障碍
- 批准号:
8595179 - 财政年份:2012
- 资助金额:
$ 3.29万 - 项目类别:
相似海外基金
Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
- 批准号:
EP/Y000331/1 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
- 批准号:
10677295 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
- 批准号:
10635599 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
- 批准号:
10752320 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
- 批准号:
478927 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
- 批准号:
10855703 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
- 批准号:
10654210 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
- 批准号:
10733915 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
- 批准号:
10667952 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
- 批准号:
10726986 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:














{{item.name}}会员




